GE Healthcare has announced the acquisition of SeqWright, a provider of nucleic acid sequencing and other genomic services.
GE Healthcare has announced the acquisition of SeqWright, a provider of nucleic acid sequencing and other genomic services.
This purchase complements Clarient, a unit of GE Healthcare, and provides a platform for Clarient to expand its clinical diagnostic offerings.
Pascale Witz, President and CEO of GE Healthcare, Medical Diagnostics, commented, “Combining the expertise and capabilities of the two companies will enable GE Healthcare to offer a substantially wider range of services to the biopharmaceutical, diagnostic and research industries and eventually to patients and health care providers.”
Fei Lu, President and CEO of SeqWright, said, “This partnership will put us in a position to apply the power of new direct detection technologies to clinical and companion diagnostics, potentially revolutionizing the way healthcare decisions are made.”
For more information please visit ref="http://www.gehealthcare.com">www.gehealthcare.com
A Review of the Latest Separation Science Research in PFAS Analysis
October 17th 2024This review aims to provide a summary of the most current analytical techniques and their applications in per- and polyfluoroalkyl substances (PFAS) research, contributing to the ongoing efforts to monitor and mitigate PFAS contamination.
Identifying PFAS in Soil Samples
October 17th 2024Jonathan Zweigle of the University Tübingen spoke with LCGC International about his work using non-targeted screening based on high-resolution mass spectrometry (HRMS) to detect PFAS in soil samples. HRMS allows scientists to determine the elemental and isotopic composition of a sample with high accuracy.